PMI's IQOS and cigarette ads in Israel.

Dec.15.2022
PMI's IQOS and cigarette ads in Israel.
Philip Morris International (PMI) used legal loopholes to market smoking products to Orthodox Jewish communities in Israel.

The leading global tobacco company Philip Morris International (PMI) has taken advantage of a legal loophole in Israel's ban on advertising smoking products, targeting the extremely conservative Orthodox (Haredi) community in Israel through advertising campaigns, thus promoting smoking addiction among the residents of that region.


A new study led by Israeli doctoral student Amal Khayat and co-authored by Yael Bar-Zeev and researchers from the Braun School of Public Health and Community Medicine at Hebrew University in Israel was recently published in the academic journal "Tobacco Control". Titled "IQOS by PMI and cigarette advertising in the Israeli media: a content analysis across regulatory periods and target audience segments", the study examines the content of tobacco advertisements in Israel targeting specific groups of consumers.


Researchers analyzed marketing data from PMI to study the differences in advertising expenditures among several major population groups in Israel over the past four years, including the general population, Haredi communities, Arabic speakers, and Russian speakers.


Khayat stated, "In light of regulatory changes restricting tobacco product advertising, we have analyzed advertising expenditures for all PMI cigarette brands and IQOS brand (a heated tobacco stick introduced to the local market in December 2016).


Although restrictions on tobacco product advertising led to a significant decrease in the company's marketing expenditures, research shows that the company has been using legal loopholes in printing machines to subvert targets and maximize profits as much as possible.


Dr. Bar-Zeev explained that despite the law coming into effect, the company continued to spend nearly 3 million New Shekels on advertising, with a focus on print media. Although the law restricts print ads to one per newspaper, 40% of IQOS ads were huge double-page spreads that effectively doubled the advertising space for the product, while still being considered a single allowable ad under the law.


Another strategy utilized by PMI is to include QR codes in their advertisements, which allows readers to scan and view additional content outside of what is printed in the newspaper.


Furthermore, the advertisement shows individuals using IQOS devices to smoke in enclosed public spaces, despite laws prohibiting the use of any tobacco products in these areas. According to researchers, such ads give the impression that this behavior is legal, thereby taking advantage of the innocence of most consumers who may not be aware of these distinctions.


The study also found that prior to the enactment of this law, PMI significantly increased their advertising towards all reviewed populations, with a particular focus on the Haredi community, who had the lowest smoking rates in Israel before being targeted with PMI's marketing tactics.


According to Bar-Zeev, "Our data indicates that since introducing IQOS electronic cigarettes, 216 targeted advertisements have been released, of which 55% were created for the ultra-Orthodox community, 6% were created for the Arab public, and the rest were created for Russian-speaking audiences.


Similarly, 87% of cigarette ads are targeted towards the Haredi community, which is a surprising discovery as the company repeatedly claims to only be interested in marketing its products to existing smokers.


Bar-Zeev stated that the company is expected to focus on the population with the highest smoking rates in Israel - Arab males - rather than a population with almost no smokers.


According to research findings, Israel's 24th parliament has decided to cancel the exemption for print media advertising, but has ultimately postponed the implementation of this step for seven years. During the discussion, a series of additional restrictions were decided upon for this transition period, including the prohibition of using coupons, QR codes, and cigarette packaging that does not include mandatory plain packaging in print ads.


Bar-Zeev concluded that the restrictions were only a drop in the bucket because the study proved that tobacco companies found creative ways to continue marketing their products and addicting new generations despite the limitations. The researchers suggested that only a complete and immediate ban on all forms of advertisement, along with strict enforcement, could prevent such a scenario from happening.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | Philip Morris Korea Launches TEREA Limona Pearl, Expanding Fresh Blend Capsule Lineup to Five
Product | Philip Morris Korea Launches TEREA Limona Pearl, Expanding Fresh Blend Capsule Lineup to Five
Philip Morris Korea launched TEREA Limona Pearl in South Korea on August 31, 2026, expanding the TEREA Fresh Blend capsule tobacco stick lineup from four variants to five. Designed for the IQOS ILUMA series, the new stick combines a capsule with what the company calls a Fresh Filter. Philip Morris Korea describes the product as offering an aromatic, refreshing flavor profile with a cooling sensation, with an additional fresh note released when the capsule is crushed. The recommended retail price is KRW 4,800 per pack, with sales through IQOS stores and convenience stores nationwide. No reliable evidence has been found that the same Limona Pearl SKU was previously officially launched in another major IQOS market.
Sep.01
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Smoore Seeks to Toss CCELL Price-Fixing Claim as Court Weighs Vertical Distribution Versus Horizontal Conspiracy
Smoore Seeks to Toss CCELL Price-Fixing Claim as Court Weighs Vertical Distribution Versus Horizontal Conspiracy
Smoore and four authorized U.S. CCELL distributors are asking a California federal court to permanently dismiss a core antitrust claim brought by direct purchasers. Plaintiffs allege that Smoore coordinated minimum wholesale prices, customer allocation and limits on price competition among distributors, amounting to a per se unlawful horizontal conspiracy. The defendants say the alleged conduct reflects ordinary vertical relationships between a manufacturer and its distributors. The court previously dismissed a similar claim, and the latest dispute centers on whether the second amended complaint adds sufficient facts to establish a horizontal agreement.
Sep.14
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands reaffirmed its FY26 guidance in its October 8 pre-close trading update, forecasting double-digit net revenue growth in next-generation products and share gains across heated tobacco, vape and modern oral. Tobacco net revenue is expected to grow at a low-single-digit rate, marking a sixth consecutive year of growth. The company has completed its £1.45 billion FY26 share repurchase and announced a £1.5 billion buyback for FY27. Group adjusted operating profit is expected to increase 3% to 5%, while free cash flow is forecast to exceed £2.2 billion.
Oct.09